Abstract:In the field of medicinal chemistry, the discovery of novel compounds with therapeutic potential is of utmost importance. However, the conventional approach to drug discovery, relying on high-throughput screening (HTS), encounters limitations such as reagent availability and labor costs. Although a hit-finding campaign starts with a virtual screen of millions of compounds, the hit-to-lead and lead optimization stages often require designing, synthesizing, and profiling thousands of analogs before selecting clinical candidates. Recent advances offer an innovative solution - the virtual generation of billions of synthetically feasible compounds with an impressive 80% success rate for synthesis. This breakthrough has the potential to significantly expand the chemical space available for purchase and experimental validation, bringing about a revolution in the field. Our study presents a comprehensive approach to compound discovery and optimization, harnessing quantitative high-throughput screening (qHTS), chemical databases, and reaction-based enumeration. To further enhance the synthesis process and gain deeper insights into compound formation, we utilize the Reaction Cookbook from Biosolveit, which comprises reaction SMARTs for around 300 chemical reactions. By employing this wide range of reactions, we aim to uncover the full spectrum of a chemotype's potential and customize its structure to optimize desired properties. As an illustration of this approach, our work on the ALDH3A1 project resulted in the synthesis of 50 compounds, with 21 of them exhibiting activity (negative curve class values; hit-rate ~42%). Among these active compounds, 6 displayed IC50 values lower than 30 µM and efficacy values less than -50%, with the most potent compound achieving an impressive potency of 447 nM. This study demonstrates the successful synergy between in-silico reaction-based analogs enumeration, molecular modeling and AI/ML-based techniques in identifying compounds with improved biological activity, offering promising prospects for the development of ALDH3A1-targeting agents as potential cancer therapeutics. Computational workflows developed in this study can be used for similar target-based drug discovery campaigns.

Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound

Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4

Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators

Deep Lead Optimization: Leveraging Generative AI for Structural Modification

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

AI-driven drug discovery: identification and optimization of ALDH3A1 selective inhibitors with nanomolar activity

Integration of Genetic Algorithms and Deep Learning for the Generation and Bioactivity Prediction of Novel Tyrosine Kinase Inhibitors

Structure-Based de Novo Molecular Generator Combined with Artificial Intelligence and Docking Simulations

REINVENT 2.0: An AI Tool for De Novo Drug Design

De novo generation of dual-target ligands using adversarial training and reinforcement learning

De Novo Generation and Identification of Novel Compounds with Drug Efficacy Based on Machine Learning

Identification of Novel Tyrosinase Inhibitors with Nanomolar Potency Using Virtual Screening Approaches

Artificial intelligence for prediction of biological activities and generation of molecular hits using stereochemical information

Artificial Intelligence in De novo Drug Design: Are We Still There?

Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process

Mining for Potent Inhibitors through Artificial Intelligence and Physics: A Unified Methodology for Ligand Based and Structure Based Drug Design

A comprehensive review of molecular optimization in artificial intelligence‐based drug discovery

Combining generative artificial intelligence and on-chip synthesis for de novo drug design

3D-Qsar and Molecular Fragment Replacement Study on Diaminopyrimidine and Pyrrolotriazine Alk Inhibitors

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

Artificial intelligence in multi-objective drug design